A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (NSC#737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01540565

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:37:13.693832+00:00

Published At

2019-03-19T00:00:00+00:00

Record Updated At

2019-07-23

Results Posted At

2019-03-19

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Ovarian Epithelial Tumor", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2019-07-23"

protocolSection.identificationModule.nctId

"NCT01540565"

protocolSection.identificationModule.officialTitle

"A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (NSC#737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2019-03-19"

Study condition terms

• BRCA1 Mutation Carrier (protocolSection.conditionsModule.conditions)
• BRCA2 Mutation Carrier (protocolSection.conditionsModule.conditions)
• Ovarian Epithelial Tumor (protocolSection.conditionsModule.conditions)
• Recurrent Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
• Recurrent Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
• Recurrent Primary Peritoneal Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.